Literature DB >> 15912287

Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer.

Shigeki Takashima1, Takeo Kosaka.   

Abstract

More than 20% of the patients with advanced gastric cancer display para-aortic lymph node (PAL) metastasis. Numerous retrospective comparative studies have reported an improved prognosis using an extensive lymph node dissection (D2) with PAL dissection, compared with D2 alone. However, many issues associated with a PAL dissection remain, such as the importance of stage migration, learning curves, and micrometastasis. This review focuses on the results and controversial issues associated with a PAL dissection. The depth of tumor invasion correlates with PAL metastasis, and whether PAL should be dissected in patients with T2 tumors remains controversial. The rate of PAL positivity is higher for cancers involving tumors of the upper third of the stomach. The most important lymphatic terminals for the stomach seem to comprise the a2 lateroaortic and b1 interaorticocaval PAL areas in tumors of the upper third and lower third, respectively. While the 5-year survival rate is about 10% after D2 plus a PAL dissection, patients with a potentially curative operation live longer. Early major complications after a PAL dissection occur in 25% of all cases, predominantly due to a pancreatectomy. A randomized clinical study evaluating a PAL dissection was launched in 1995 in Japan. Furthermore, numerous reports of patients with gastric cancer and PAL metastases responding to chemotherapy should also be considered.

Entities:  

Mesh:

Year:  2005        PMID: 15912287     DOI: 10.1007/s00595-004-2976-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  11 in total

Review 1.  Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?

Authors:  Yasuhiro Kodera; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Surg Today       Date:  2014-11-01       Impact factor: 2.549

Review 2.  Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer.

Authors:  Zhen Wang; Jun-Qiang Chen; Yun-Fei Cao
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

Review 3.  Lymph node dissection in the resection of gastric cancer: review of existing evidence.

Authors:  Yutaka Tanizawa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

4.  D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery.

Authors:  Jian-Kun Hu; Kun Yang; Bo Zhang; Xin-Zu Chen; Zhi-Xin Chen; Jia-Ping Chen
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

Review 5.  Current status of conversion surgery for stage IV gastric cancer.

Authors:  Jun Kinoshita; Takahisa Yamaguchi; Hideki Moriyama; Sachio Fushida
Journal:  Surg Today       Date:  2021-01-23       Impact factor: 2.549

6.  Lymph node dissection in curative gastrectomy for advanced gastric cancer.

Authors:  Shigeyuki Tamura; Atsushi Takeno; Hirofumi Miki
Journal:  Int J Surg Oncol       Date:  2011-06-14

7.  A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.

Authors:  Qi He; Long Ma; Yang Li; Guoli Li
Journal:  BMC Gastroenterol       Date:  2016-01-18       Impact factor: 3.067

8.  Is There Any Role for D3 Lymphadenectomy in Gastric Cancer?

Authors:  Gerassimos N Douridas; Stefanos K Pierrakakis
Journal:  Front Surg       Date:  2018-03-22

9.  A case of stage IV gastric cancer with para-aortic lymph node metastasis showing pathological complete response after neoadjuvant chemotherapy.

Authors:  Yuki Katsura; Takehiro Okabayashi; Manabu Matsumoto; Kazuhide Ozaki; Yuichi Shibuya
Journal:  Surg Case Rep       Date:  2020-01-10

10.  Factors associated with metastasis in superior mesenteric vein lymph node in subtotal gastrectomy for gastric cancer: Retrospective case control study.

Authors:  Won Ho Han; Jungnam Joo; Bang Wool Eom; Keun Won Ryu; Young-Woo Kim; Myeong-Cherl Kook; Hong Man Yoon
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.